<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04989322</url>
  </required_header>
  <id_info>
    <org_study_id>475-0708-MT-Lung</org_study_id>
    <nct_id>NCT04989322</nct_id>
  </id_info>
  <brief_title>Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC</brief_title>
  <official_title>A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Joanne CHIU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adding chemotherapy or anti-VEGF to immunotherapy is an emerging strategy to enhance the&#xD;
      efficacy of immunotherapy in many cancers. This phase 2 study aims to explore the preliminary&#xD;
      efficacy of combination pembrolizumab with lenvatinib and chemotherapy in NSCLC patients with&#xD;
      sensitizing EGFR, ALK, or ROS1 genetic aberration refractory to standard targeted therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>24 months</time_frame>
    <description>Proportion of patients who have a confirmed CR or PR per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Time from randomization to the first documented disease progression per RECIST 1.1 or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>Time from randomization to death from any cause or last follow-up date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence, severity as graded by NCI CTCAE v5.0, seriousness and relationship to study medication of adverse events (AEs)</measure>
    <time_frame>24 months</time_frame>
    <description>Safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Nsclc</condition>
  <condition>EGFR Activating Mutation</condition>
  <condition>EGF-R Positive Non-Small Cell Lung Cancer</condition>
  <condition>ALK Gene Rearrangement Positive</condition>
  <condition>ROS1 Gene Rearrangement</condition>
  <condition>ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg Q3W</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>8 mg daily</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 Q3W</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC5 Q3W</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven NSCLC&#xD;
&#xD;
          -  Unresectable or metastatic NSCLC, including squamous cell carcinoma, harboring&#xD;
             sensitizing EGFR, ALK, or ROS1 genetic aberrations who have received standard of care&#xD;
             targeted therapy and have progressed on treatment. Patients with known T790M mutation&#xD;
             should have received osimertinib and failed.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1&#xD;
&#xD;
          -  ECOG performance status ≤ 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequately controlled blood pressure&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to immunotherapy or chemotherapy&#xD;
&#xD;
          -  Active untreated brain metastasis and/or carcinomatous meningitis&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  History of (noninfectious) pneumonitis that required systemic steroids or current&#xD;
             pneumonitis/interstitial lung disease&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medications&#xD;
&#xD;
          -  Baseline proteinuria ≥ 1 g/24 hrs&#xD;
&#xD;
          -  Electrolyte abnormalities that have not been corrected&#xD;
&#xD;
          -  Significant cardiovascular impairment&#xD;
&#xD;
          -  Gastrointestinal pathology that might affect the absorption of lenvatinib&#xD;
&#xD;
          -  Preexisting grade ≥ 3 gastrointestinal or non gastrointestinal fistula&#xD;
&#xD;
          -  Bleeding or thrombotic disorders or subjects at risk for severe hemorrhage&#xD;
&#xD;
          -  Radiographic evidence of intratumoral caviations, encasement, or invasion of a major&#xD;
             blood vessel&#xD;
&#xD;
          -  Known history of tuberculosis&#xD;
&#xD;
          -  Active, acute, or chronic clinically significant infections requiring therapy,&#xD;
             including hepatitis B, hepatitis C, and HIV&#xD;
&#xD;
          -  ECG with long QTc interval ≥ 470 ms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Joanne Chiu, MBBS</last_name>
    <phone>+852-22553111</phone>
    <email>jwychiu@hku.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr James Ho, MBBS</last_name>
    <phone>+852-22553111</phone>
    <email>jhocm@hku.hk</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr Joanne CHIU</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

